Emmanuèle Attout, formerly an audit partner at PricewaterhouseCoopers, has been appointed as a non-executive director of ThromboGenics NV and will join the audit committee of the company. Belgium-based ThromboGenics has an ophthalmology focus and has a product for an eye disease known as symptomatic vitreomacular adhesion on the market in the US.
ThromboGenics announced the appointment on 22 January 2015.
Copyright 2015 Evernow Publishing Ltd